Adverse drug reaction (ADR) is the 6th leading cause of death globally. Understanding the common variations in genes coding for drug metabolism and transport proteins helps inform decisions related to adverse drug reactions and medication management for better health outcomes and cost-savings while delivering personalized medicine.

This form of personalized medicine has become a reality with advancements in technologies that help with understanding of common variation in genes encoding for drug metabolism and drug transporters. The use of pharmacogenetic information earlier in clinical trials enables better understanding of participant drug response leading to optimal trial outcomes. 

Applied Biosystems microarray solutions offer a portfolio of targeted pharmacogenomics (PGx) assays as well as whole genome research arrays as summarized below.

PGx ArrayPharmacoFocus ArrayPharmacoScan Array
Genomewide arrayPrecision Medicine diversity arraySARS-CoV-2 Research Array

NEW! Applied Biosystems Axiom Human Genotyping SARS-CoV-2 Research Array

Are you interested in important SNP markers associated with COVID-19 susceptibility?

Request details ›

Featured solutions

Axiom PharmacoFocus Solution

The Axiom PharmacoFocus Solution is ideal for pre-emptive pharmacogenomics with the flexibility of a multi-gene test panel aligned with your pharmacogenomics research, whether it takes place in labs, academic hospitals, healthcare centers, or the pharma industry. It is a configurable, flexible, and scalable solution, developed to accelerate pharmacogenomic research.

The Axiom PharmacoFocus assay provides comprehensive coverage of high evidence content (88% of variants in PharmGKB highest levels of evidence) with 2,000 markers in 150 genes covering population diversity. This unique solution offers total flexibility to choose few or all from a comprehensive set of 2,000 high-evidence ADME variants to generate high accuracy pharmacogenomic SNP, CNV, and HLA typing, all in a single workflow at lower cost.

The flexibility to choose the number of markers relevant for given applications enables customers to deliver right solution at the right price point. In addition, we have partnered with Coriell Lifesciences to integrate genotyping results into Coriell’s medication management reporting system to support customers’ specific needs enabling full solution. 

Learn more about the PharmacoFocus Solution ›
Customize a gene panel suitable for your pharmacogenomics goals ›

Axiom PharmacoScan Solution

The PharmacoScan Solution offers broad coverage of industry-relevant, multi-ethnic content and the capability to address markers in complex genes using an array-plate platform that has superior lot-to-lot reproducibility. The PharmacoScan Solution targets functional variations in the key genes involved in the absorption, distribution, metabolism, and excretion (ADME) of commonly prescribed medications and can help reduce the lengthy timelines and complexities within the drug discovery process.

Unlike solutions that analyze only high-evidence markers, the PharmacoScan Solution presents a more comprehensive view for genotyping for pharmacogenomic risk by analyzing 4627 high- to low-evidence markers within nearly 1,200 genes in a single assay. The solution includes copy number variation calling and interrogating predictive markers in complex genes.

Learn more about the PharmacoScan Solution ›

Axiom Analysis Suite

A complete solution to data analysis for all Axiom arrays. From sample and plate QC to automated genotype calling and SNP classification, this easy-to-use software performs analysis in a single step and allows you to view QC results, summary tables, and SNP cluster graphs. Axiom Analysis Suite together with the PharmacoScan Solution provide support for star allele and translation tables for key actionable genes.

Learn more about Axiom Analysis Suite ›

For Research Use Only. Not for use in diagnostic procedures.